vs
NATIONAL RURAL UTILITIES COOPERATIVE FINANCE CORP（NRUC）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
NATIONAL RURAL UTILITIES COOPERATIVE FINANCE CORP的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.5倍（$53.8M vs $35.5M），NATIONAL RURAL UTILITIES COOPERATIVE FINANCE CORP净利率更高（41.6% vs -304.2%，领先345.8%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -52.7%），NATIONAL RURAL UTILITIES COOPERATIVE FINANCE CORP自由现金流更多（$105.1M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs -1.5%）
美国国家农村公用事业合作金融公司（CFC）是一家由成员所有的非盈利合作社，为美国农村电力合作网络提供金融产品。该公司成立于1969年，创立初衷是从资本市场筹集资金，补充美国农业部农村公用事业局面向电力合作社的贷款项目。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
NRUC vs RXRX — 直观对比
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $53.8M | $35.5M |
| 净利润 | $22.4M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | — | -304.8% |
| 净利率 | 41.6% | -304.2% |
| 营收同比 | -52.7% | 681.7% |
| 净利润同比 | -74.0% | 39.6% |
| 每股收益（稀释后） | — | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | $53.8M | — | ||
| Q4 25 | $59.0M | $35.5M | ||
| Q3 25 | $47.3M | $5.2M | ||
| Q2 25 | $66.9M | $19.2M | ||
| Q1 25 | $113.7M | $14.7M | ||
| Q4 24 | $182.0M | $4.5M | ||
| Q3 24 | $61.7M | $26.1M | ||
| Q2 24 | — | $14.4M |
| Q1 26 | $22.4M | — | ||
| Q4 25 | $19.6M | $-108.1M | ||
| Q3 25 | $4.8M | $-162.3M | ||
| Q2 25 | $73.1M | $-171.9M | ||
| Q1 25 | $86.0M | $-202.5M | ||
| Q4 24 | $144.4M | $-178.9M | ||
| Q3 24 | $-163.8M | $-95.8M | ||
| Q2 24 | — | $-97.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | -304.8% | ||
| Q3 25 | — | -3327.6% | ||
| Q2 25 | — | -916.8% | ||
| Q1 25 | — | -1297.9% | ||
| Q4 24 | — | -4042.4% | ||
| Q3 24 | — | -377.1% | ||
| Q2 24 | — | -697.4% |
| Q1 26 | 41.6% | — | ||
| Q4 25 | 33.2% | -304.2% | ||
| Q3 25 | 10.1% | -3135.3% | ||
| Q2 25 | 109.3% | -894.2% | ||
| Q1 25 | 75.6% | -1373.3% | ||
| Q4 24 | 79.4% | -3935.5% | ||
| Q3 24 | -265.7% | -367.5% | ||
| Q2 24 | — | -676.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | $-0.17 | ||
| Q3 25 | — | $-0.36 | ||
| Q2 25 | — | $-0.41 | ||
| Q1 25 | — | $-0.50 | ||
| Q4 24 | — | $-0.56 | ||
| Q3 24 | — | $-0.34 | ||
| Q2 24 | — | $-0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $240.7M | $743.3M |
| 总债务越低越好 | $28.9B | $9.6M |
| 股东权益账面价值 | $3.1B | $1.1B |
| 总资产 | $39.9B | $1.5B |
| 负债/权益比越低杠杆越低 | 9.40× | 0.01× |
8季度趋势，按日历期对齐
| Q1 26 | $240.7M | — | ||
| Q4 25 | $304.5M | $743.3M | ||
| Q3 25 | $257.1M | $659.8M | ||
| Q2 25 | $134.7M | $525.1M | ||
| Q1 25 | $245.4M | $500.5M | ||
| Q4 24 | $347.1M | $594.4M | ||
| Q3 24 | $264.7M | $427.6M | ||
| Q2 24 | — | $474.3M |
| Q1 26 | $28.9B | — | ||
| Q4 25 | $27.3B | $9.6M | ||
| Q3 25 | $27.9B | $11.9M | ||
| Q2 25 | $27.2B | $14.2M | ||
| Q1 25 | $27.5B | $16.4M | ||
| Q4 24 | $26.7B | $19.0M | ||
| Q3 24 | $26.3B | $20.5M | ||
| Q2 24 | — | $22.9M |
| Q1 26 | $3.1B | — | ||
| Q4 25 | $3.1B | $1.1B | ||
| Q3 25 | $3.0B | $1.0B | ||
| Q2 25 | $3.1B | $919.1M | ||
| Q1 25 | $3.0B | $933.9M | ||
| Q4 24 | $2.9B | $1.0B | ||
| Q3 24 | $2.8B | $524.6M | ||
| Q2 24 | — | $584.4M |
| Q1 26 | $39.9B | — | ||
| Q4 25 | $39.1B | $1.5B | ||
| Q3 25 | $38.8B | $1.4B | ||
| Q2 25 | $38.3B | $1.3B | ||
| Q1 25 | $37.8B | $1.3B | ||
| Q4 24 | $37.1B | $1.4B | ||
| Q3 24 | $36.5B | $726.5M | ||
| Q2 24 | — | $775.9M |
| Q1 26 | 9.40× | — | ||
| Q4 25 | 8.95× | 0.01× | ||
| Q3 25 | 9.21× | 0.01× | ||
| Q2 25 | 8.81× | 0.02× | ||
| Q1 25 | 9.15× | 0.02× | ||
| Q4 24 | 9.14× | 0.02× | ||
| Q3 24 | 9.44× | 0.04× | ||
| Q2 24 | — | 0.04× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $105.6M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $105.1M | $-47.3M |
| 自由现金流率自由现金流/营收 | 195.2% | -133.1% |
| 资本支出强度资本支出/营收 | 0.9% | 3.5% |
| 现金转化率经营现金流/净利润 | 4.72× | — |
| 过去12个月自由现金流最近4个季度 | $428.2M | $-378.3M |
8季度趋势，按日历期对齐
| Q1 26 | $105.6M | — | ||
| Q4 25 | $38.9M | $-46.1M | ||
| Q3 25 | $82.3M | $-117.4M | ||
| Q2 25 | $207.5M | $-76.4M | ||
| Q1 25 | $150.3M | $-132.0M | ||
| Q4 24 | $63.8M | $-115.4M | ||
| Q3 24 | $36.7M | $-59.2M | ||
| Q2 24 | — | $-82.2M |
| Q1 26 | $105.1M | — | ||
| Q4 25 | $38.3M | $-47.3M | ||
| Q3 25 | $82.0M | $-117.6M | ||
| Q2 25 | $202.8M | $-79.6M | ||
| Q1 25 | $149.0M | $-133.8M | ||
| Q4 24 | $62.7M | $-116.7M | ||
| Q3 24 | $35.4M | $-63.8M | ||
| Q2 24 | — | $-83.4M |
| Q1 26 | 195.2% | — | ||
| Q4 25 | 64.9% | -133.1% | ||
| Q3 25 | 173.4% | -2272.5% | ||
| Q2 25 | 303.1% | -413.9% | ||
| Q1 25 | 131.0% | -907.4% | ||
| Q4 24 | 34.5% | -2567.7% | ||
| Q3 24 | 57.5% | -244.6% | ||
| Q2 24 | — | -578.5% |
| Q1 26 | 0.9% | — | ||
| Q4 25 | 1.1% | 3.5% | ||
| Q3 25 | 0.7% | 4.7% | ||
| Q2 25 | 7.0% | 16.4% | ||
| Q1 25 | 1.1% | 12.4% | ||
| Q4 24 | 0.6% | 28.6% | ||
| Q3 24 | 2.1% | 17.5% | ||
| Q2 24 | — | 8.2% |
| Q1 26 | 4.72× | — | ||
| Q4 25 | 1.99× | — | ||
| Q3 25 | 17.27× | — | ||
| Q2 25 | 2.84× | — | ||
| Q1 25 | 1.75× | — | ||
| Q4 24 | 0.44× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
